TargetMol

α-Thujone

Product Code:
 
TAR-T8193
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8193-10mg10mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8193-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8193-25mg25mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8193-50mg50mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8193-100mg100mg£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Thujone is an inhibitor of ACh with an IC50 value of 24.7μM.
CAS:
546-80-5
Formula:
C10H16O
Molecular Weight:
152.237
Pathway:
NF-κb; Autophagy; Membrane transporter/Ion channel; Apoptosis; Neuroscience; Microbiology/Virology; Immunology/Inflammation; Metabolism
Purity:
0.98
SMILES:
CC(C)[C@@]12C[C@@H]1[C@@H](C)C(=O)C2
Target:
Apoptosis; Reactive Oxygen Species; GABA Receptor; AChR; Parasite; Autophagy

References

Lachenmeier D W , Emmert J , Kuballa T , et al. Thujone?Cause of absinthism?[J]. forensic science international, 2006, 158(1):1-8. Sultan A , Yang K H S , Isaev D , et al. Thujone inhibits the function of ? 7 -nicotinic acetylcholine receptors and impairs nicotine-induced memory enhancement in one-trial passive avoidance paradigm[J]. Toxicology, 2017, 384:23-32.